Size of Hepatitis C Treatment Market Points to Upside for Shares of Gilead (GILD)
Tweet Send to a Friend
Deutsche Bank analysts today increased their price target on Gilead Sciences (NASDAQ: GILD) to $75.00 (from $68.00). The upgrade came ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
